All In Biotech

Drug Trial Radar · NCT06800404

"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

"A Phase 2, Open Label, Efficacy and Safety Study of Autologous HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Actual

Start

May 2, 2025

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Sponsor type
Industry
First posted
Jan 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.

Conditions

  • Relapsing Remitting Multiple Sclerosis (RRMS)
  • Multiple Sclerosis

Interventions

  • Autologous HB-adMSCsDrug

    Autologous HB-adMSCs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument scoresTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hope Biosciences Research Foundation

    Sugar Land, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.